Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online “RNAi Roundtables” that it is hosting during July and August. Each event will be webcast live on the Investors section of the company’s website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

The newly added RNAi Roundtable topics include:

ALN-PCSsc for the treatment of HypercholesterolemiaThursday, August 14 @ 4:00 p.m. – 5:00 p.m. ET

Kevin Fitzgerald, Ph.D., Senior Director, Research
Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer
Guest Speaker: Christie Ballantyne, M.D., Professor of Medicine, Physiology, and Molecular and Human Genetics, and Chief, Department of Medicine, Sections of Cardiology and Cardiovascular Research at Baylor College of Medicine

ALN-AAT for the treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseWednesday, August 20 @ 12:30 p.m. – 1:30 p.m. ET

Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer
Guest Speaker: David Brenner, M.D., Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of California, San Diego

ALN-AS1 for the treatment of Hepatic PorphyriasThursday, August 21 @ 4:00 p.m. – 5:00 p.m. ET

Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
Moderator: Barry Greene, President and Chief Operating Officer
Guest Speaker: Karl Anderson, M.D., FACP, Professor, Departments of Preventive Medicine and Community Health (Division of Human Nutrition) and Internal Medicine (Division of Gastroenterology), and Director, Porphyria Laboratory & Center

These new events complement the series of already scheduled RNAi Roundtables that the company plans to host. The complete list of RNAi Roundtables, including links to the replays of the previously held events, can be found at www.alnylam.com/capella.

Alnylam will be reviewing its progress with ALN-HBV in development for Hepatitis B Virus (HBV) Infection in an RNAi Roundtable webinar to be held at 9:30 a.m. ET today, and can be accessed by clicking here.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company’s “Alnylam 5x15TM” product strategy. Alnylam’s genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an RNAi therapeutic targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia; and other programs yet to be disclosed. As part of its “Alnylam 5x15” strategy, as updated in early 2014, the company expects to have six to seven genetic medicine product candidates in clinical development - including at least two programs in Phase 3 and five to six programs with human proof of concept - by the end of 2015. Alnylam is also developing ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection. The company’s demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna Therapeutics, a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

Alnylam Pharmaceuticals, Inc.Cynthia Clayton, 617-551-8207Vice President, Investor Relations andCorporate CommunicationsorSpectrumLiz Bryan (Media), 202-955-6222 x2526

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024